A
Avammune Therapeutics
Biotech company developing multi-modal cancer therapies, including ADAR1 and ENPP1 inhibitors and radioligand therapeutics for solid tumors
About Avammune Therapeutics
Avammune Therapeutics is an R&D-driven drug discovery company developing next-generation oncology therapies for hard-to-treat solid tumors. The company combines multiple therapeutic modalities: an ADAR1 p150 inhibitor (AVA ADR 001), an orally available ENPP1 inhibitor (AVA NP 695), and a radioligand therapeutic in development. AVA ADR 001 is a small-molecule inhibitor of ADAR1 that modulates the innate immune system, with preclinical data showing an interferon response via an MDA5-dependent mechanism, selectivity for the p150 isoform, and anti-tumor efficacy in the B16F10 melanoma syngeneic mouse model, including synergy when combined with anti-PD1 therapy. AVA NP 695 is an ENPP1 inhibitor advancing toward IND-enabling studies. The company was founded by serial biotech entrepreneurs previously behind Aten Porus Lifesciences and Oraxion Therapeutics, and is backed by investors including Shastra VC, Capital 2B, IvyCap Ventures, 1Crowd, Kotak Alternate Asset Managers and The Chennai Angels. Avammune is headquartered in Philadelphia, with an R&D affiliate in Bangalore, India.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | May 2025 | $12M | $48M | IvyCap Ventures · 1Crowd · Capital 2B · Shastra VC | ↗ |
| LATE VC✓Equity / VC | Jul 2022 | $0 | — | The Chennai Angels | ↗ |
Growth signals
Latest recorded traffic for Avammune Therapeutics is 1.1K monthly website visits, up 96.4% over the last three months. Avammune Therapeutics's team grew 120% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Avammune Therapeutics in the Philadelphia ecosystem
The Avammune Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Capital 2B
Shastra VC
IvyCap Ventures- 1C1Crowd
Kotak Alternate Asset Managers
Series B and later1 investor entered at this stage
The Chennai Angels
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Avammune Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Avammune Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









